

Nicolas Pottier

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1875226/publications.pdf>

Version: 2024-02-01

42
papers

1,957
citations

279798

23
h-index

243625

44
g-index

46
all docs

46
docs citations

46
times ranked

3898
citing authors

#	ARTICLE	IF	CITATIONS
1	Pervasive role of the long noncoding <scp>RNA DNM3OS</scp> in development and diseases. Wiley Interdisciplinary Reviews RNA, 2023, 14, e1736.	6.4	5
2	A Double-Negative Feedback Interaction between miR-21 and PPAR- δ in Clear Renal Cell Carcinoma. Cancers, 2022, 14, 795.	3.7	8
3	MUC1 Mitigates Renal Injury and Inflammation in Endotoxin-Induced Acute Kidney Injury by Inhibiting the TLR4-MD2 Axis and Reducing Pro-inflammatory Macrophages Infiltration. Shock, 2021, 56, 629-638.	2.1	13
4	COVID-19-related collapsing glomerulopathy revealing a rare risk variant of APOL1: lessons for the clinical nephrologist. Journal of Nephrology, 2021, 34, 373-378.	2.0	13
5	The FibromiR miR-214-3p Is Upregulated in Duchenne Muscular Dystrophy and Promotes Differentiation of Human Fibro-Adipogenic Muscle Progenitors. Cells, 2021, 10, 1832.	4.1	4
6	Diagnostic utility of whole-genome sequencing for nephronophthisis. Npj Genomic Medicine, 2020, 5, 38.	3.8	14
7	Comparative analysis of the perception of nuclear risk in two populations (expert/non-expert) in France. Energy Reports, 2020, 6, 2288-2298.	5.1	4
8	NHP2 deficiency impairs rRNA biogenesis and causes pulmonary fibrosis and H \ddot{A} yeraal \ddot{A} “Hreidarsson syndrome. Human Molecular Genetics, 2020, 29, 907-922.	2.9	38
9	The stem cell-associated gene expression signature allows risk stratification in pediatric acute myeloid leukemia. Leukemia, 2019, 33, 348-357.	7.2	44
10	Prevention of Cisplatin-Induced Acute Kidney Injury: A Systematic Review and Meta-Analysis. Drugs, 2019, 79, 1567-1582.	10.9	49
11	The nuclear hypoxia-regulated NLUCAT1 long non-coding RNA contributes to an aggressive phenotype in lung adenocarcinoma through regulation of oxidative stress. Oncogene, 2019, 38, 7146-7165.	5.9	75
12	Caveolin-1 rs4730751 single-nucleotide polymorphism may not influence kidney transplant allograft survival. Scientific Reports, 2019, 9, 15541.	3.3	1
13	Non-Coding RNAs as New Therapeutic Targets in the Context of Renal Fibrosis. International Journal of Molecular Sciences, 2019, 20, 1977.	4.1	23
14	The Long Noncoding RNA DNM3OS Is a Reservoir of FibromiRs with Major Functions in Lung Fibroblast Response to TGF- β 2 and Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 184-198.	5.6	78
15	Tacrolimus-induced nephrotoxicity in mice is associated with microRNA deregulation. Archives of Toxicology, 2018, 92, 1539-1550.	4.2	22
16	Dual role of MUC1 mucin in kidney ischemia-reperfusion injury: Nephroprotector in early phase, but pro-fibrotic in late phase. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2017, 1863, 1336-1349.	3.8	16
17	Targeting miR-21 decreases expression of multi-drug resistant genes and promotes chemosensitivity of renal carcinoma. Tumor Biology, 2017, 39, 101042831770737.	1.8	51
18	Impact of MicroRNAs in the Cellular Response to Hypoxia. International Review of Cell and Molecular Biology, 2017, 333, 91-158.	3.2	37

#	ARTICLE	IF	CITATIONS
19	miR-21-5p renal expression is associated with fibrosis and renal survival in patients with IgA nephropathy. <i>Scientific Reports</i> , 2016, 6, 27209.	3.3	67
20	miR-30c and miR-193 are a part of the TGF β -dependent regulatory network controlling extracellular matrix genes in liver fibrosis. <i>Journal of Digestive Diseases</i> , 2015, 16, 513-524.	1.5	57
21	Donor caveolin 1 (CAV1) genetic polymorphism influences graft function after renal transplantation. <i>Fibrogenesis and Tissue Repair</i> , 2015, 8, 8.	3.4	10
22	Donor ABCB1 genetic polymorphisms influence epithelial-to-mesenchyme transition in tacrolimus-treated kidney recipients. <i>Pharmacogenomics</i> , 2014, 15, 2011-2024.	1.3	14
23	MUC1 drives epithelial-mesenchymal transition in renal carcinoma through Wnt/ β -catenin pathway and interaction with SNAIL promoter. <i>Cancer Letters</i> , 2014, 346, 225-236.	7.2	77
24	FibromiRs: translating molecular discoveries into new anti-fibrotic drugs. <i>Trends in Pharmacological Sciences</i> , 2014, 35, 119-126.	8.7	79
25	MicroRNA Target Identification: Lessons from HypoxamiRs. <i>Antioxidants and Redox Signaling</i> , 2014, 21, 1249-1268.	5.4	12
26	MUC1-C nuclear localization drives invasiveness of renal cancer cells through a sheddase/gamma secretase dependent pathway. <i>Oncotarget</i> , 2014, 5, 754-763.	1.8	23
27	miR-199a-5p Is Upregulated during Fibrogenic Response to Tissue Injury and Mediates TGFbeta-Induced Lung Fibroblast Activation by Targeting Caveolin-1. <i>PLoS Genetics</i> , 2013, 9, e1003291.	3.5	210
28	Increased Circulating miR-21 Levels Are Associated with Kidney Fibrosis. <i>PLoS ONE</i> , 2013, 8, e58014.	2.5	175
29	Isolation and Characterization of a Primary Proximal Tubular Epithelial Cell Model from Human Kidney by CD10/CD13 Double Labeling. <i>PLoS ONE</i> , 2013, 8, e66750.	2.5	79
30	Xenobiotic Metabolism and Disposition in Human Lung Cell Models: Comparison with In Vivo Expression Profiles. <i>Drug Metabolism and Disposition</i> , 2012, 40, 1953-1965.	3.3	70
31	Genetic polymorphisms in ARID5B, CEBPE, IKZF1 and CDKN2A in relation with risk of acute lymphoblastic leukaemia in adults: a group for research on adult acute lymphoblastic leukaemia (GRAALL) study. <i>British Journal of Haematology</i> , 2012, 150, 599-613.	2.5	18
32	Xenobiotic metabolism and disposition in human lung: Transcript profiling in non-tumoral and tumoral tissues. <i>Biochimie</i> , 2011, 93, 1012-1027.	2.6	40
33	Profiling gene expression of whole cytochrome P450 superfamily in human bronchial and peripheral lung tissues: Differential expression in non-small cell lung cancers. <i>Biochimie</i> , 2010, 92, 292-306.	2.6	48
34	Identification of Keratinocyte Growth Factor as a Target of microRNA-155 in Lung Fibroblasts: Implication in Epithelial-Mesenchymal Interactions. <i>PLoS ONE</i> , 2009, 4, e6718.	2.5	192
35	Pharmacogenetics in Acute Lymphoblastic Leukemia. <i>Seminars in Hematology</i> , 2009, 46, 39-51.	3.4	55
36	The SWI/SNF Chromatin-Remodeling Complex and Glucocorticoid Resistance in Acute Lymphoblastic Leukemia. <i>Journal of the National Cancer Institute</i> , 2008, 100, 1792-1803.	6.3	61

#	ARTICLE	IF	CITATIONS
37	Antileukemic drug effects in childhood acute lymphoblastic leukemia. <i>Expert Review of Clinical Pharmacology</i> , 2008, 1, 401-413.	3.1	1
38	In Vivo Response to Methotrexate Forecasts Outcome of Acute Lymphoblastic Leukemia and Has a Distinct Gene Expression Profile. <i>PLoS Medicine</i> , 2008, 5, e83.	8.4	75
39	Relationships between Early Inflammatory Response to Bleomycin and Sensitivity to Lung Fibrosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2007, 176, 1098-1107.	5.6	22
40	Expression of SMARCB1 modulates steroid sensitivity in human lymphoblastoid cells: identification of a promoter snp that alters PARP1 binding and SMARCB1 expression. <i>Human Molecular Genetics</i> , 2007, 16, 2261-2271.	2.9	38
41	Functional characterization of genetic polymorphisms identified in the human cytochrome P450 4F12 (CYP4F12) promoter region. <i>Biochemical Pharmacology</i> , 2004, 67, 2231-2238.	4.4	12
42	Human CYP4F12 genetic polymorphism: identification and functional characterization of seven variant allozymes. <i>Biochemical Pharmacology</i> , 2004, 68, 2417-2425.	4.4	10